[{"id":"c72ecd8f-9c23-45c8-aceb-c2281207ef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT07141771","created_at":"2025-08-30T13:51:58.696Z","updated_at":"2025-08-30T13:51:58.696Z","phase":"Phase 1/2","brief_title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","source_id_and_acronym":"NCT07141771","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • etoposide IV • irinotecan • topotecan • AiRuiYi (fluzoparib) • Zepzelca (lurbinectedin) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-26"},{"id":"9a0a8faa-2764-48be-bddc-53cde9f97223","acronym":"LiFFT","url":"https://clinicaltrials.gov/study/NCT05918640","created_at":"2023-06-26T14:09:13.345Z","updated_at":"2025-02-25T15:13:34.219Z","phase":"Phase 1/2","brief_title":"Lurbinectedin in FET-Fused Tumors","source_id_and_acronym":"NCT05918640 - LiFFT","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4","pipe":"","alterations":" ","tags":["EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-13"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"fcb868e2-5523-48f4-b199-227a152f0dc1","acronym":"LURBIMUNE","url":"https://clinicaltrials.gov/study/NCT05572476","created_at":"2022-10-07T14:00:03.928Z","updated_at":"2025-02-25T15:00:40.239Z","phase":"Phase 2","brief_title":"Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer","source_id_and_acronym":"NCT05572476 - LURBIMUNE","lead_sponsor":"Institut Bergonié","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • etoposide IV • Zepzelca (lurbinectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2024-06-05"},{"id":"e2cd7df4-a3bf-46be-9b4c-885f319f5bef","acronym":"PM1183-A-014-15","url":"https://clinicaltrials.gov/study/NCT02611024","created_at":"2021-12-03T00:53:57.424Z","updated_at":"2024-07-02T16:35:06.918Z","phase":"Phase 1/2","brief_title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","source_id_and_acronym":"NCT02611024 - PM1183-A-014-15","lead_sponsor":"PharmaMar","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 05/06/2016","start_date":" 05/06/2016","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-30"},{"id":"519407a2-e161-4bce-9dc1-be6550116e9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800587","created_at":"2023-04-05T14:03:42.889Z","updated_at":"2024-07-02T16:35:12.781Z","phase":"Phase 2","brief_title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","source_id_and_acronym":"NCT05800587","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • pemetrexed • etoposide IV • irinotecan • topotecan • Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 02/22/2023","start_date":" 02/22/2023","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-03-26"},{"id":"07d712f7-22e2-4f57-ad7d-c2400a080233","acronym":"EMERGE-201","url":"https://clinicaltrials.gov/study/NCT05126433","created_at":"2021-11-19T13:53:37.793Z","updated_at":"2024-07-02T16:35:17.551Z","phase":"Phase 2","brief_title":"Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201)","source_id_and_acronym":"NCT05126433 - EMERGE-201","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2 • HRD","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 03/03/2022","start_date":" 03/03/2022","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-02-26"},{"id":"731ab927-ac32-42ee-9011-baa1124b987d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229588","created_at":"2022-02-12T17:48:13.004Z","updated_at":"2024-07-02T16:35:21.201Z","phase":"Phase 2","brief_title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","source_id_and_acronym":"NCT05229588","lead_sponsor":"HonorHealth Research Institute","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-02"},{"id":"6652628c-ad51-4797-8f15-72f4094ba21f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05578326","created_at":"2022-10-13T17:58:14.557Z","updated_at":"2024-07-02T16:35:29.032Z","phase":"Phase 2","brief_title":"Study of Trilaciclib and Lurbinectidin","source_id_and_acronym":"NCT05578326","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin) • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 07/25/2024","primary_completion_date":" 07/25/2024","study_txt":" Completion: 07/25/2026","study_completion_date":" 07/25/2026","last_update_posted":"2023-11-16"},{"id":"4dacc8db-356a-480d-b423-f6e0b948d9b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04607954","created_at":"2021-01-19T20:31:50.970Z","updated_at":"2024-07-02T16:35:42.142Z","phase":"Phase 2","brief_title":"Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer","source_id_and_acronym":"NCT04607954","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • topotecan • Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-07-24"},{"id":"04e5e604-a320-4706-8606-1273d722ce7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02454972","created_at":"2021-01-18T11:46:37.871Z","updated_at":"2024-07-02T16:35:54.260Z","phase":"Phase 2","brief_title":"Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors","source_id_and_acronym":"NCT02454972","lead_sponsor":"PharmaMar","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Completed","enrollment":" Enrollment 345","initiation":"Initiation: 08/25/2015","start_date":" 08/25/2015","primary_txt":" Primary completion: 09/18/2020","primary_completion_date":" 09/18/2020","study_txt":" Completion: 09/18/2020","study_completion_date":" 09/18/2020","last_update_posted":"2023-03-02"},{"id":"b9646e03-3b93-41fe-a534-1decec5bf67f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042934","created_at":"2021-09-13T14:56:00.294Z","updated_at":"2024-07-02T16:36:17.321Z","phase":"Phase 1b/2","brief_title":"Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma","source_id_and_acronym":"NCT05042934","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EWSR1 • FLI1 • WRN • RECQL","pipe":"","alterations":" ","tags":["EWSR1 • FLI1 • WRN • RECQL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Zepzelca (lurbinectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2022-02-10"},{"id":"22868803-f5d5-40f1-83eb-f84f0a14e3a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01525589","created_at":"2021-01-18T06:25:51.592Z","updated_at":"2024-07-02T16:36:40.682Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer","source_id_and_acronym":"NCT01525589","lead_sponsor":"PharmaMar","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 overexpression","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 06/13/2012","start_date":" 06/13/2012","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2020-09-25"},{"id":"de2c7fe1-2cba-4e07-a13f-cabdd8c7381a","acronym":"CORAIL","url":"https://clinicaltrials.gov/study/NCT02421588","created_at":"2023-10-15T04:13:07.134Z","updated_at":"2024-07-02T16:36:46.670Z","phase":"Phase 3","brief_title":"Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients","source_id_and_acronym":"NCT02421588 - CORAIL","lead_sponsor":"PharmaMar","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • topotecan • Zepzelca (lurbinectedin)"],"overall_status":"Completed","enrollment":" Enrollment 442","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 10/12/2018","primary_completion_date":" 10/12/2018","study_txt":" Completion: 10/12/2018","study_completion_date":" 10/12/2018","last_update_posted":"2020-04-03"},{"id":"ba24ef7d-1f4f-49ea-9992-e392030963e9","acronym":"POLA","url":"https://clinicaltrials.gov/study/NCT02684318","created_at":"2021-01-19T11:44:36.764Z","updated_at":"2025-02-25T14:57:32.272Z","phase":"Phase 1/2","brief_title":"Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors","source_id_and_acronym":"NCT02684318 - POLA","lead_sponsor":"Poveda, Andrés, M.D.","biomarkers":" BRCA1 • PTEN • PARP1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • PTEN • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zepzelca (lurbinectedin)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2017-06-22"}]